GF
TXMD icon

Gabelli Funds’s TherapeuticsMD TXMD Stock Holding History

Gabelli Funds’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,000
Closed -$19.3K – 1118
2024
Q2 		$19.3K Hold
12,000
– – ﹤0.01% 1050
2024
Q1 		$27.5K Sell
12,000
-17,000
-59% -$39.4K ﹤0.01% 1047
2023
Q4 		$65.3K Sell
29,000
-2,000
-6% -$4.83K ﹤0.01% 1043
2023
Q3 		$93.6K Hold
31,000
– – ﹤0.01% 1043
2023
Q2 		$128K Hold
31,000
– – ﹤0.01% 1040
2023
Q1 		$116K Hold
31,000
– – ﹤0.01% 1059
2022
Q4 		$173K Hold
31,000
– – ﹤0.01% 1077
2022
Q3 		$206K Sell
31,000
-3,000
-9% -$24.3K ﹤0.01% 1148
2022
Q2 		$338K Buy
+34,000
New +$325K ﹤0.01% 1093

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gabelli Funds's TXMD Position: Q3 2024 in Review

Gabelli Funds sold out of TherapeuticsMD (TXMD) in Q3 2024, closing a stake of 12,000 shares — an estimated $19.3K sold.

Gabelli Funds first reported a position in TXMD in Q2 2022 and held it in 9 quarters. The position peaked at $338K in Q2 2022. 37 funds tracked by Wall St. Rank hold TXMD as of Q3 2024.

  • Gabelli Funds reported no remaining TherapeuticsMD position as of Q3 2024 after selling out during the quarter.
  • Gabelli Funds sold 12,000 TherapeuticsMD shares in Q3 2024, an estimated $19.3K.
  • Gabelli Funds first reported a position in TherapeuticsMD in Q2 2022 and held it in 9 quarters.
  • Gabelli Funds's TherapeuticsMD position peaked at $338K in Q2 2022.
  • 37 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2024.

Based on Gabelli Funds's 13F filing for Q3 2024, filed 13 Nov 2024.